-
NEWS: US FDA approves Narcan (4mg naloxone nasal spray) for over-the-counter purchase/use
(From the US FDA press release) Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Today’s action paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online. Read the complete press release. Posted March 29, 2023
-
Protocol Update: CTN-0139
March 15, 2023 CTN-0139, the Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) Trial, is studying a collaborative care intervention for polysubstance use involving opioids and/or stimulants, in adult primary care patients. Collaborative care is a team-based approach to managing chronic conditions that has been effective for depression and other behavioral health conditions, and has the potential to transform the delivery of substance use treatment in primary care settings. This HEAL-funded CTN trial will test the Co-Care model versus enhanced usual care to reduce substance use and improve substance use-related functioning. The study will be conducted at 5 primary care sites (FQHCs and FQHC look-alikes). A pilot study will launch in February 2024 at one site, and the main study will start in August 2024 at all sites. The Lead Team is currently conducting site selection activities and will be scheduling interviews in the coming weeks. If you have clinics who may be interested in participating, please contact Jasmine Fernando Jasmine.Fernando@nyulangone.org. The Lead Investigator is Jennifer McNeely, MD, MS from the NY Node, and Co-Lead Investigator is Jane Liebschutz, MD, MPH from the Appalachian Node. For more information, contact the Project Director, Rebecca Stone Rebecca.Stone@nyulangone.org.
-
Recording Available: Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future
The Office of Research Training, Diversity, and Disparities is offering a series titled Profiles of Excellence: Focus on Diversity. This webinar, held on March 6, 2023 from 4-5pm EST, featured Ayana Jordan, MD, PhD, of NYU Grossman School of Medicine, talking about “Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future.” View the recording here. (Passcode: Yyr!6b?j)
-
Webinar: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD (April 6, Northeast Node)
Join the CTN Northeast Node on April 6, 2023 (12pm-1pm ET) for the latest in their Science Series: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD? with Eva Quirion, NP, PhD This presentation will explore the science behind extended release (XR) buprenorphine and field experiences in the use of XR buprenorphine in a primary care setting. This talk will also address ways to bring this medication to patients and if this treatment makes financial sense. 1.0 AMA PRA Category 1 CME available! Join the Zoom meeting here (no registration necessary)
-
REGISTER NOW! CTN Annual Steering Committee Meeting: April 24-26, 2023
March 2, 2023 Registration is now open for this year’s CTN Annual Steering Committee Meeting, April 24-26, 2023! The 2023 CTN Annual Steering Committee Meeting is being held in-person at the Bethesda North Marriott Hotel and Conference Center (book your reservation here!) in Rockville, Maryland, from April 24–26, 2023. For those unable to attend in person, all plenary sessions and some ancillary sessions will be broadcast via Zoom. The level of interaction available virtually will vary by session. Both in-person and virtual attendees will register on the Zoom Events platform: Both methods will give you the same virtual experience and will not affect in-person attendance! The “Information” tab includes hotel, travel, agenda and other meeting details. More information will be added to this site as it becomes available. The “Frequently Asked Questions” guide at the bottom of this email has more information regarding meeting logistics, including how to change your registration type. Important Links Individuals with disabilities who need sign language interpreting and/or other reasonable accommodations to participate in this event, should contact Sean Randol at (240) 863-0507 or srandol@leedmci.com or through the Federal Relay (1-800-877-8339). Requests should be made at least five business days in advance of the event. Please contact the LMCi Logistics Team at ctnsupport@leedmci.com with questions. We are excited about being back in person and look forward to seeing you at this important meeting!
-
NIDA HIV Research Program Seminar: Substance Use and HIV Latency (April 26, 1-2pm ET)
Mark your calendars for Wednesday April 26th, 1-2 pm ET for this unique opportunity to interact with a leading researcher at the intersection of HIV and substance use. The NIDA HIV Research Program (HRP) is pleased to announce the next presentation in its Seminar Series: A vicious cycle: The impact of inflammation and substance use on the control of HIV latency in microglia by Dr. Jonathan Karn, Reinberger, Professor & Chair of the Department of Molecular Biology & Microbiology at Case Western Reserve University School of Medicine. Dr. Karn has been studying transcriptional control in HIV since the mid-1980s. His current research focuses on the impact of substance use on the regulation of HIV transcription and latency in microglial cells. Register here to receive your link.
-
Job posting: NIDA Program Official/Program Specialist and Two Contractor Positions
February 13, 2023 NIDA is hiring for this new program, named American Indian and Alaska Native Collective Research Effort to Enhance Wellness Program (AIAN CREW). In brief, the NIH HEAL Initiative is funding a program to support Tribes and American Indian/Alaska Native (AI/AN) serving organizations and communities to respond to the opioid/drug overdose crisis by establishing or expanding research infrastructure and capacity for Tribal research entities to conduct research related to all facets of the opioid/overdose crisis, including substance misuse, mental health related factors, and the management of pain. It will address data insufficiencies by providing support to improve data and surveillance of factors that contribute to the opioid/drug overdose crisis at the local level (including local data and connections to state, regional and national data. Increasing research capacity will include supporting the conduct of Tribally or community prioritized research. There will also be funding for technical assistance and provide support for the development of any needed partnerships to achieve all program goals. A Tribal Consultation informed the development of this effort. NIDA is hiring staff for this research effort:
-
Save the Date & Call for Posters: 2023 CTN Steering Committee Meeting, April 24-26
February 3, 2023 Save the Date The 2023 CTN Steering Committee meeting will be held at the Bethesda North Marriott Hotel & Conference Center (North Bethesda, MD) on April 24-26, 2023. More information on registration and logistics coming soon! Call for Posters Sharing of the results, experiences, techniques, and observations from performing our trials is a critical and exciting part of the CTN experience. To that end, CTN members are encouraged to submit posters for display at the 2023 CTN Annual Steering Committee Meeting Poster Session to be held on April 24, 2023. Poster submissions should be relatable to the CTN either directly (i.e. reporting on CTN studies, data, etc.) or indirectly (i.e. information that informs potential future CTN projects). As in previous years, we will consider new posters as well as posters that were presented at meetings over the past year. Event: CTN Annual Steering Committee Meeting Poster SessionVenue: Bethesda North Marriott Hotel & Conference Center (North Bethesda, MD)Date: Monday, April 24, 2023Time: 5:30 – 7:30 p.m. ET Guidelines:
-
Missing the Mark: Medication Access in Specialty Addiction Treatment Settings for Youth with OUD (March 17, 11amPT)
February 2, 2023 The CTN Youth SIG is pleased to invite you to an upcoming presentation/webinar: Missing the Mark: Medication Access in Specialty Addiction Treatment Settings for Youth with Opioid Use DisorderMarch 17, 2023 | 11am-12pm PT Justine W. Welsh, MD, Associate Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine The objectives of the presentation are to 1) Describe a decreasing trend in buprenorphine prescribing for youth with opioid use disorder (OUD) 2) Recognize attitudes/beliefs among addiction treatment providers towards medication for OUD in youth 3) Propose new areas of research to increase utilization of MOUD across treatment settings. Join the Zoom Session Here
-
NIDA INVEST Postdoctoral Fellowship International Scholars – Special Application Deadline: April 1, 2023
January 25, 2023 NIDA International Program is accepting applications for international postdoctoral researchers for the INVEST Drug Use and Addiction Research Fellowship. This combines postdoctoral research training in the United States with professional development activities and grant-writing guidance to form a unique program for drug use and addiction scientists. Fellowship: The 12-month INVEST fellowship provides rigorous postdoctoral research training with a NIDA grantee at a U.S. institution, professional development activities that help establish personal relationships with NIDA grantees and NIDA officials, a stipend for living and personal expenses, and an allowance to cover the cost of health insurance and professional development activities. Eligibility: INVEST applicants are required to be international researchers with a doctoral degree and a minimum of 2 years of postdoctoral experience, to have citizenship or permanent residency in a country other than the United States, and to have a proficiency in written and spoken English. INVEST Mentors: INVEST mentors must be NIDA-funded researchers in the United States. Their NIDA-funded grants must be active throughout the proposed fellowship period. Reference: Steven W. Gust, Judy McCormally, & Nei-Hyun Park (2021). Increasing evidence-based substance use interventions globally: The National Institute on Drug Abuse postdoctoral fellowships, Substance Abuse, 42(4):397-406, https://doi.org/10.1080/08897077.2021.1975874. Contact NIDA: For questions about the INVEST Postdoctoral Fellowship, contact ip@nida.nih.gov.
